Mental Health Startup Funding 2025-2026

What are all the funding deals in the mental health market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play mental health companies between August 2025 and July 2026. We define the mental health market as services and products that diagnose, treat, or clinically manage mental and substance use disorders.

Each row shows the company, what it does, its category, the deal date, the funding stage, the round size, the region, the main investors, and the announcement source. For a wider view of how this market is evolving, we cover it in our Mental Health market report.

How active has fundraising been in the mental health market?

As of July 2026, fundraising in the mental health market has been active but not evenly distributed. Over the past 12 months, companies raised 26 disclosed equity rounds and $1.09B in combined capital.

Deal activity was fairly consistent for part of the period. The mental health market averaged 2.36 disclosed deals per month, with a median of 3 deals per month.

The dollar pattern was much more volatile. February 2026 produced $350.2M, March 2026 produced $272M, and January 2026 produced only $4.6M.

This means the mental health market had real activity, but its headline funding total depends heavily on a few active months. February and March 2026 together accounted for $622.2M, or 57.00% of total capital.

If you want to go deeper on the companies behind this activity, see our market report covering mental health funding.

How concentrated has fundraising been in the mental health market?

As of July 2026, fundraising in the mental health market has been highly concentrated. Over the past 12 months, the top 1 deal represented 19.24% of all capital, while the top 3 reached 48.09%.

The top 5 deals captured 60.92% of disclosed funding. By the top 10 deals, the share reached 78.88%, which leaves the remaining 16 deals with a much smaller capital pool.

This concentration matters because the total market figure can look stronger than the typical company experience. The median round was $25M, while the average was $41.98M.

The mental health market therefore had both scaled winners and a functioning mid-market. But the headline total should be read through the lens of top-round dependency.

How much of the mental health funding signal is driven by outliers?

As of July 2026, a large part of the mental health funding signal is driven by outliers. Over the past 12 months, rounds above $50M represented 19.23% of deals but $665M of disclosed capital.

That means six large rounds materially shaped the market narrative. Talkiatry, Syremis Therapeutics, Grow Therapy, Salma Health, Gilgamesh Pharma, and Radial each crossed the $50M threshold.

Excluding rounds above $50M reduces total capital from $1.09B to $426.6M. That shows the core market below megaround level was less than 40% of headline funding.

This is the key reading rule for the mental health market. The market looked large because a few companies raised very large rounds, not because every category received equal capital.

Is the mental health market broad with many targets, or narrow with few fundable companies?

As of July 2026, the mental health market is moderately broad by deal count but narrow by geography and capital concentration. Over the past 12 months, the dataset includes 26 deals across 26 unique companies.

The one-company-per-deal pattern suggests a wide surface of fundable targets. Investors backed therapy providers, psychiatry platforms, clinics, clinical tools, addiction treatment, and psychiatric medication companies.

But the market is not broad geographically. Every qualifying disclosed deal came from North America, so the visible funding signal is really a North American clinical care and reimbursement signal.

It is also not broad by capital distribution. The top 10 deals captured 78.88% of funding, which means many companies raised, but a small group defined the dollar story.

Is mental health mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the mental health market is split between early-stage formation and scaled follow-on funding. Over the past 12 months, Seed and Series A together represented $542.6M, or 49.71% of total capital.

Series A was the largest stage by capital, with $490.7M and 44.95% of disclosed dollars. That shows investors were willing to underwrite new clinical infrastructure before full late-stage maturity.

Seed was frequent but small. Seed rounds accounted for 7 of 26 deals, yet only $51.9M, or 4.75% of disclosed capital.

Late-stage capital was also meaningful but narrow. Series D+ had only 2 deals, but those two rounds represented $360M and 32.98% of total capital.

For more context on how stages map to business models, explore our deeper analysis of the mental health market.

Which categories attract the most investor attention in mental health?

As of July 2026, Therapy Care Providers attracted the most investor attention in the mental health market by deal count. Over the past 12 months, the category produced 9 deals, or 34.62% of all disclosed rounds.

Therapy Care Providers also led on total dollars, with $293M and 26.84% of disclosed capital. But its capital share was lower than its deal share, which suggests repeat funding without outsized checks.

Clinical Mental Health Apps were second by deal count, with 5 deals and 19.23% of activity. They raised $96.8M, which was only 8.87% of capital.

Psychiatric Medication Services and Mental Health Clinics each produced 4 deals. Together, they show that investors funded both new treatment modalities and clinic-based delivery models.

Which categories attract disproportionately large checks in the mental health market?

As of July 2026, Psychiatry Care Platforms attracted the most disproportionately large checks in the mental health market. Over the past 12 months, the category had only 11.54% of deals but captured 23.36% of capital.

Its capital share to deal share ratio was 2.02, the highest in the dataset. That makes psychiatry access the clearest capital-overweighted segment relative to deal frequency.

Psychiatric Medication Services also attracted large checks. The category had 15.38% of deals and 23.71% of capital, supported by a $165M Syremis Therapeutics round and a $60M Gilgamesh Pharma round.

Clinical Mental Health Apps moved in the opposite direction. They represented 19.23% of deals but only 8.87% of capital, giving them the lowest capital share to deal share ratio at 0.46.

Which geographies matter most for fundraising in the mental health market?

As of July 2026, North America is the only geography that matters in this disclosed mental health funding dataset. Over the past 12 months, North America accounted for 26 deals and $1.09B of capital.

This does not mean mental health demand is only North American. It means publicly disclosed qualifying equity funding, under this strict clinical definition, was entirely North America-based in the dataset.

The geographic signal should therefore be read carefully. It is a funding-visibility and reimbursement-market signal, not a complete global demand map.

North America’s dominance also affects category interpretation. Therapy providers, psychiatry platforms, and clinic models in this dataset are largely shaped by payer coverage, provider networks, and U.S.-style access bottlenecks.

We cover the geographic and category implications in more detail in our full market deck on mental health.

Is the mental health opportunity set broad or concentrated in one hub?

As of July 2026, the mental health opportunity set is concentrated in one disclosed funding hub. Over the past 12 months, 100% of qualifying deals and 100% of capital came from North America.

That concentration is unusually clean. There were no qualifying disclosed equity rounds from Europe, Asia-Pacific, Latin America, Africa, or the Middle East in the final sample.

The result should not be read as proof that other regions lack mental health companies. It shows that the publicly visible, clinically pure-play, disclosed equity dataset was U.S.-centric in practice.

This matters for interpretation because the strongest themes are tied to North American care delivery. Reimbursement, clinician shortages, specialty access, and payer-aligned models shape the entire dataset.

Is mental health a market of small experiments or scaled financings?

As of July 2026, the mental health market contains both small experiments and scaled financings, but the dollars lean toward scaled rounds. Over the past 12 months, the median round was $25M and the average round was $41.98M.

The deal-size distribution is broad. There were 3 deals between $0.3M and $5M, 8 deals between $5M and $20M, 9 deals between $20M and $50M, and 6 deals above $50M.

Most companies were not raising tiny experimental checks. Seventeen of 26 deals were at least $20M, which suggests investors wanted meaningful clinical scale or strong evidence of market validation.

At the same time, megarounds drove most of the dollar story. Rounds above $50M represented only 19.23% of deals but accounted for $665M of total capital.

If you want to compare this with other clinical and healthcare markets, see our market report on mental health funding trends.

What does round size say about investor conviction in the mental health market?

As of July 2026, round size in the mental health market shows investors had strongest conviction around scarce capacity, payer access, and clinically differentiated treatment. Over the past 12 months, the largest checks went to psychiatry, therapy networks, clinics, and psychiatric medicines.

Talkiatry raised $210M, Grow Therapy raised $150M, and Salma Health raised $80M. These are not lightweight wellness products; they are care-delivery or clinical infrastructure models.

Drug-development risk also remained fundable when tied to serious neuropsychiatric conditions. Syremis Therapeutics raised $165M, while Gilgamesh Pharma raised $60M and Amani Therapeutics raised $25M.

The smaller average checks for Clinical Mental Health Apps suggest software-only models still need stronger proof. Investors appeared more comfortable funding tools when they were attached to supervised care, provider workflows, or measurable clinical operations.

Who are the investors that appear the most in mental health fundraising?

As of July 2026, only a small group of investors appeared more than once in mental health fundraising. Over the past 12 months, General Catalyst was the most frequent named repeat investor, with 3 disclosed deals.

General Catalyst appeared in Somethings, Radial, and InStride Health. That mix spans youth mental health, interventional psychiatry, and specialty care for anxiety and OCD.

Andreessen Horowitz appeared in 2 deals, Talkiatry and Ease Health. That pair suggests interest in both full-stack psychiatry delivery and behavioral health operating infrastructure.

Town Hall Ventures appeared in Marble Health and Jimini Health, while .406 Ventures appeared in FamilyWell Health and InStride Health. Repeat investor activity was real, but still selective rather than market-wide.

One important caveat is that round announcements usually disclose participation, not individual check size. So repeat-investor counts are more reliable than dollar-by-investor rankings in the mental health market.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.